Clinical Trial Update: A Study of the Efficacy, Safety and Pharmacokinetics of RPH-051 and Perjeta® in Combination With Trastuzumab and Docetaxel as the 1st Line Therapy in Patients With HER2-positive Breast Cancer [Phase 3]

View source ↗

Summary

Phase 3 study evaluating the efficacy, safety, and pharmacokinetics of RPH-051 in combination with Perjeta, trastuzumab, and docetaxel as first-line therapy for…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• DOCETAXEL (DOCETAXEL)
• Perjeta (pertuzumab)
• RPH-051
• Trastuzumab (trastuzumab)

Snippet

Sponsor: R-Pharm | Conditions: Locally Advanced Breast Cancer, Metastatic Breast Cancer | Phase 3 | Status: ACTIVE_NOT_RECRUITING